No Influence of DTNBP1 Polymorphisms on the Response to Aripiprazole

Abstract

Aims: The aim of the present study was to investigate pos- sible influences of a panel of markers in the dysbindin gene DTNBP1 (rs3213207, rs1011313, rs2005976, rs760761 and rs2619522) on the clinical outcome and side effects associated to the treatment with aripiprazole in schizophrenic patients. Methods: Efficacy was assessed at baseline and weeks 1, 2, 4, 6 and 8 using the Clinical Global Impression Severity and Improvement Scales, the Brief Psychiatric Rating Scale and the Schedule for the Assessment of Negative Symptoms. Side effects were evaluated by the Simpson-Angus, Barnes Akathisia and Abnormal Involuntary Movement Scales. Multivariate analysis of covariance was used to test possible influences of single nucleotide polymorphisms on clinical and safety scores. Analysis of haplotypes was also performed. Results: No relevant association between DTNBP1 variants and clinical or safety scores was observed. Additionally, haplotype analysis did not reveal any significant association with clinical and safety scores at any time as well. Conclusion: Our data suggest no association between the investigated alleles and genotypes in DTNBP1 and the response to aripiprazole. However, because several limitations characterize the present study, further investigations are required.

Antipsychotics switching strategies in real life: A longitudinal study in clinical practice

“…Most literature on AP switching focus on proposals [3][4][5]16,20 , study overall effectiveness of AP switching 21 or study long term or short term effects and safety of switching methods 9,13 . Whereas long term effects of switching methods appear to be small 13 , on the short term the switching method can possibly precipitate side effects or induce psychosis 3,4 , affecting patient compliance and indirectly compromising long term success of AP therapy.…”

“…Whereas long term effects of switching methods appear to be small 13 , on the short term the switching method can possibly precipitate side effects or induce psychosis 3,4 , affecting patient compliance and indirectly compromising long term success of AP therapy. As no final evidence is yet available for superiority of a single switching method, switching APs still remains an art rather than science.…”

“…The metanalysis of Remington et al 7 has been criticised as the four studies involved [8][9][10][11][12] were industry-sponsored, favoring any switch outcomes 2 . Recently, Pae et al 13 have documented support for the gradual switch to aripiprazole and other authors favour gradual switching approaches as well [2][3][4]14 .…”

Case–control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics

“…The sample has been previously investigated by our group with regard to other gene variants (e.g. [14,15]). …”